On May 12, 2021, the Board of Directors of Flexion Therapeutics, Inc. appointed Frederick W. Driscoll as Chief Financial Officer, principal financial officer, and principal accounting officer, effective upon the termination of Mr. Arkowitz’s employment with Flexion. Mr. Driscoll, served as Chief Financial Officer of Flexion from 2013 to 2017. Prior to joining Flexion in 2013, Mr. Driscoll served as Chief Financial Officer at Novavax, Inc; Chief Executive Officer at Genelabs Technologies, Inc., from 2008 to 2009, and as its Chief Financial Officer from 2007 to 2008; Chief Financial Officer at Astraris, Inc.; and Chief Executive Officer at OXiGENE, Inc., from 2002 to 2006. The company also announced that David Arkowitz, CFO, will step down on May 31, 2021, and will be succeeded by Fred Driscoll.